Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Refers to the total number of somatic mutations that exist within a tumor’s genome.
A subset of these mutations may result in expressed proteins, termed neo-antigens, that are not recognized by the host’s immune system as self, and therefore have the potential to be immunogenic, leading to an anti-tumor immune-mediated response.
Tumors with a high mutation burden may have a higher rate of neo-antigens which, in principle, would be expected to be more immunogenic than tumors with comparatively low mutation burden.
The results are determined as follows:
* based on TCGA data of ~5000 samples from 9 cancer types (BRCA, BLCA, COAD, LUAD, LUSC, OV, SKCM, STAD, UCEC)
Our dedicated Client Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.Please click here to see the specimen preparation and shipping instructions
contact us in order to arrange for all the logistics.Please click here
you are already aware of the process of sending a sample, in order to download all the related forms.Please click here